Log in to add personal notes on this page.
Sphingolipids are lipids abundant in the nervous system, and lysosomal enzymes break them down. Each sphingolipidosis lacks one lysosomal enzyme or helper protein, so its own substrate is stored. Where that substrate is most abundant decides the picture: the body (Gaucher type 1, Fabry), the brain (Krabbe, metachromatic leukodystrophy, Tay-Sachs), or both (Niemann-Pick).
Four routes, all ending at ceramide.
- GM2 ganglioside → GM3 ganglioside: hexosaminidase A, an alpha (HEXA) and beta (HEXB) heterodimer, with the GM2 activator protein (GM2A) as a substrate-specific cofactor. Blocked in all three GM2 gangliosidoses: Tay-Sachs disease at the alpha chain, and Sandhoff disease and GM2 activator deficiency at the beta chain and the activator.
- GM3 ganglioside → lactosylceramide: lysosomal sialidase (NEU1) removes the sialic acid.
- globotriaosylceramide (Gb3) → lactosylceramide: alpha-galactosidase A (GLA) removes the terminal galactose. Blocked in Fabry disease.
- lactosylceramide → glucosylceramide: GM1 beta-galactosidase (GLB1) or galactocerebrosidase (GALC).
- glucosylceramide → glucose + ceramide: glucocerebrosidase (GBA1). Blocked in Gaucher disease.
- sulfatide → galactocerebroside: arylsulfatase A (ARSA) removes the sulfate. Blocked in metachromatic leukodystrophy.
- galactocerebroside → galactose + ceramide: galactocerebrosidase (GALC). Blocked in Krabbe disease.
- sphingomyelin → ceramide + phosphorylcholine: acid sphingomyelinase (SMPD1). Blocked in Niemann-Pick disease types A and B; in type C the NPC1 and NPC2 proteins (NPC1, NPC2) fail to move cholesterol out of the lysosome.
- Gaucher disease (AR): glucosylceramide fills macrophages (Gaucher cells), giving hepatosplenomegaly, anemia, thrombocytopenia, and bone crises in type 1; types 2 and 3 add neurodegeneration. GBA1 variants also raise Parkinson disease risk, in carriers too.
- Fabry disease (X-linked, the only X-linked sphingolipidosis), the most common lysosomal storage disorder: Gb3 is stored in nerve, kidney, heart, and vessel wall, giving acroparesthesias, angiokeratomas, corneal opacities, reduced sweating, then cardiac disease, stroke, and kidney failure. Females range from unaffected to as severe as males.
- Krabbe disease (AR): galactocerebroside and the toxic psychosine build up, and psychosine kills myelin-forming cells. Infantile onset at 3 to 6 months, with extreme irritability.
- Metachromatic leukodystrophy (AR): sulfatides are stored in oligodendrocytes and Schwann cells, destroying central and peripheral myelin.
- Tay-Sachs disease and Sandhoff disease and GM2 activator deficiency (AR), the three GM2 gangliosidoses: GM2 ganglioside is stored in neurons, so gray matter fails: regression, exaggerated startle, cherry-red spot. Infantile Sandhoff disease adds hepatosplenomegaly; the juvenile form does not.
- Niemann-Pick disease (AR): sphingomyelin in types A and B (type A neuronopathic and fatal by 2 to 3 years, type B visceral with lung disease); trapped cholesterol in type C, with ataxia and vertical supranuclear gaze palsy.
- White matter or gray matter: Krabbe and metachromatic leukodystrophy are leukodystrophies; Tay-Sachs affects neuronal cell bodies.
- The specific marker: blood psychosine (Krabbe, very high in infantile disease), urine sulfatides (metachromatic leukodystrophy), plasma lyso-Gb3 (Fabry), lyso-Gb1 and chitotriosidase (Gaucher), plasma oxysterols (Niemann-Pick C).
- Hexosaminidase pattern: Tay-Sachs has low A with normal B; Sandhoff has low A and low B; GM2 activator deficiency has normal A and B, because the enzyme is intact.
- Pseudodeficiency: low measured arylsulfatase A or galactocerebrosidase can come from benign alleles, so enzyme activity alone does not confirm the diagnosis.
- Cherry-red spot, from lipid in the retinal ganglion cells around the fovea, points to a GM2 gangliosidosis (Tay-Sachs, Sandhoff, or GM2 activator deficiency) or Niemann-Pick type A.
"Tay-Sachs" is HEXA, and in Niemann-Pick type C, cholesterol is trapped in the lysosome.